Attached files
| file | filename |
|---|---|
| EX-10.1 - RESEARCH AGREEMENT - MYMETICS CORP | mymx_ex101.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): December 1, 2016
(November 29, 2016)
Mymetics Corporation
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-25132
|
|
25-1741849
|
|
(State of other
jurisdiction of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS Employer
Identification No.)
|
|
Route de la
Corniche 4
1066 Epalinges,
Switzerland
|
|
NA
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: +011 41 21 653 45
35
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
[ ]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item
1.01 Entry into a Material Definitive Agreement.
On
November 28, 2016, the registrant, Mymetics Corporation, through
its Dutch subsidiary, Mymetics BV ("Mymetics"), entered into a
Research Agreement (the "Agreement"), effective October 21, 2016,
with Sanofi Pasteur Biologics, LLC ("Sanofi"), the vaccine division
of Sanofi SA. Sanofi will evaluate the immunogenicity of influenza
vaccines based on Mymetics’ proprietary virosome technology
platform in pre-clinical settings compared to egg-based split
vaccines. Mymetics expects to enter into a more extensive
collaboration with Sanofi should the evaluation by Sanofi be
positive.
The
foregoing description of the Agreement does not purport to be
complete and is qualified in its entirety by reference to the
Agreement which is filed as exhibit 10.1 to this Current Report on
Form 8-K.
The
registrant issued a press release announcing the Agreement, a copy
of which is filed as exhibit 99.1 to this Current Report on Form
8-K.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Research Agreement
effective October 21, 2016 between Sanofi Biologics, LLC and
Mymetics BV*
99.1
Press Release dated
December 1, 2016
*Portions of this
exhibit 10.1 have been omitted and separately filed with the SEC
with a request for confidential treatment.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
MYMETICS CORPORATION
|
|
|
|
|
|
|
|
|
Date: December 1,
2016
|
By:
|
/s/ Ronald
Kempers
|
|
|
|
|
Ronald
Kempers
|
|
|
|
|
President and Chief
Executive Officer
|
|
3